Detalhe da pesquisa
1.
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer.
Nature
; 629(8014): 1142-1148, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38588696
2.
Multi-omic machine learning predictor of breast cancer therapy response.
Nature
; 601(7894): 623-629, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34875674
3.
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial.
Lancet Oncol
; 21(7): 969-977, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32615110
4.
Safe de-escalation of chemotherapy in HER2-positive early breast cancer.
Lancet
; 403(10437): 1606-1607, 2024 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38582093
5.
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
Lancet
; 394(10214): 2084-2095, 2019 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31791688
6.
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
Lancet
; 393(10191): 2599-2612, 2019 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31178152
7.
Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results.
BMC Cancer
; 18(1): 391, 2018 04 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29621991
8.
Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.
Lancet Oncol
; 18(6): 755-769, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28479233
9.
Integrative analysis of copy number and gene expression in breast cancer using formalin-fixed paraffin-embedded core biopsy tissue: a feasibility study.
BMC Genomics
; 18(1): 526, 2017 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28697743
10.
Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer.
Breast Cancer Res
; 18(1): 21, 2016 Feb 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-26882907
11.
Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study.
PLoS Med
; 13(12): e1002198, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27997533
12.
Trastuzumab-associated cardiac events in the Persephone trial.
Br J Cancer
; 115(12): 1462-1470, 2016 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27875516
13.
Protective strategies to prevent trastuzumab-induced cardiotoxicity - Authors' reply.
Lancet
; 395(10223): 492-493, 2020 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32061290
14.
Intensive cisplatin/oral etoposide for epithelial ovarian cancer: the Cambridge Gynae-Oncology Centre experience: too toxic for relapse?
Anticancer Drugs
; 27(3): 239-44, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26575000
15.
Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 16(6): 656-66, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25975632
16.
Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis.
PLoS Med
; 12(2): e1001789, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25710373
17.
A Bayesian adaptive design for biomarker trials with linked treatments.
Br J Cancer
; 113(5): 699-705, 2015 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26263479
18.
A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities.
BMC Med
; 13: 306, 2015 Dec 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-26715442
19.
The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel.
Cancer Cell
; 12(6): 514-27, 2007 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18068629
20.
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial.
Lancet Oncol
; 15(2): 201-12, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24360787